EGFR and neoplasm: Moreover, the anti-tumor efficacy of sotorasib is enhanced by the EGFR inhibitor cetuximab, as the drug combination significantly reduces cell viability in vitro and potently suppresses tumor growth in a patient-derived xenograft (PDX) model (32).